glp-1 six in one oral liquid side effects LERCEA supplement for weight loss GLP-1RA Essentials in Gastroenterology: Side

and its presence will also be felt in the kitchen: Consumers and chefs will increasingly lean into AI for recipes and healthy decision-making as the use of AI in corporate and consumer kitchens will accelerate to be used, increasingly, in cooking techniques and ingredient substitutions

RTs Three Key Takeaways: GLP-1 Agonists Improve Asthma Control GLP-1 agonists like Ozempic and Mounjaro were linked to reduced asthma symptoms and medication use in obese patients, beyond their role in weight loss

Most patients tolerate the medication well, but those with existing heart conditions should be monitored closely

Although the tablet has been approved for use in the UK, it is not currently available through the NHS

Key areas of concern for decision makers and executives include: Continued rapid rates of increased utilization: Treatment guideline recommendations to prefer GLP-1 agonists and GIP/GLP-1 dual agonists over other less expensive diabetic treatments Increase in physicians awareness of obesity as a disease Stronger trust in the long-term effects and safety of GLP-1 receptor agonists Unwavering demand by individuals seeking quick weight loss solutions Additional products seeking approval and entering the market: Over 50 products are currently in clinical development for obesity and/or T2D GLP-1 agonism is being studied in combination with other mechanisms of action including GIP agonism, glucagon agonism, amylin agonism, and PYY agonism Shortages of currently marketed drugs provide opportunity for additional products to successfully enter the marketplace Additional indications for these products are gaining approval: Clinical trials are ongoing for several indications beyond the currently approved obesity and/or T2D uses Examples of therapeutic applications currently under investigation include Parkinsons and Alzheimers diseases, smoking cessation, alcoholism, and MASH The GLP-1 agonist market is rapidly evolving with significant implications for payers